To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307

Trial Title: To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307

NCT ID: NCT05783570

Condition: Advanced Hepatocellular Carcinoma

Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular

Conditions: Keywords:
GPC3
HCC
Hepatocellular Carcinoma
CAR-T

Study type: Interventional

Study phase: Phase 1

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Biological
Intervention name: EU307 CAR-T Cell
Description: - Dose to be administered: a single dose - IV administration - Dosing rate: To be administrated at a rate of approximately 2 mL/min
Arm group label: EU307 CAR-T Cell

Summary: To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy

Detailed description: A Dose-escalation, Single-arm, Open-Label, Phase 1 Study

Criteria for eligibility:
Criteria:
Inclusion Criteria: - To be eligible, subjects must meet all of the following criteria: 1. Male or female adults ≥19 years old at the time of written informed consent 2. Patients with histologically or cytologically diagnosed unresectable HCC refractory to first- or second-line standard therapy* with no other standard therapy available * Including, but not limited to atezolizumab plus bevacizumab combination therapy and tyrosine kinase inhibitors (e.g., sorafenib, lenvatinib). 3. Confirmed GPC3 positivity by IHC based on a liver tissue sample 4. At least 1 measurable lesion based on mRECIST v1.1 5. Child-Pugh score Class A or Class B(7) 6. Life expectancy ≥3 months based on the judgment of the investigator 7. ECOG PS 0 or 1 8. Patients who have adequate bone marrow, liver, and kidney functions at the time of screening: WBC ≥ 2,000 /μL ANC ≥ 1,000 /μL Platelet ≥ 80,000 /μL Hemoglobin ≥ 9.0 g/dL Albumin ≥ 2.8 g/dL AST and ALT ≤ 5ⅹULN Total bilirubin ≤ 2 x ULN Serum creatinine ≤1.5 x ULN Creatinine clearance (CrCl) ≥ 30 mL/min PT(INR) ≤1.5 x ULN 9. Negative serum pregnancy test in women of childbearing potential 10. Women of childbearing potential or men who do not plan a pregnancy during the study period and who agree to use clinically adequate methods of contraception as follows: * Hormone contraceptives (subcutaneous implants, injections, oral contraceptives, etc.), intrauterine device (IUD) (or intra uterine system [IUS]), subject's or partner's surgical sterilization (vasectomy, tubal ligation, etc.), double barrier methods (combined use of barrier methods such as combined use of cervical cap or diaphragm plus male condom) 11. Written informed consent to voluntary study participation Exclusion Criteria: - Subjects who meet any of the following criteria cannot participate in the study: Current disease and medical history 1. History or current evidence of hepatic encephalopathy 2. Patients with radiographic findings of brain metastases or spinal cord compression 3. Histologically confirmed HCC in ≥50% of the liver 4. Severe ascites requiring treatment such as paracentesis 5. History or current evidence of the following infections: - Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) - Active hepatitis B (However, if HBsAg is positive, and if it is low or undetectable HBV DNA (HBV DNA level <2,000 IU/mL) based on the site-specific criteria at screening and a prophylactic antiviral agent can be administered for 6 months after the administration of the investigational product, enrollment is possible at the discretion of the investigator.) - Active hepatitis C (However, patients who have undergone antiviral therapy and whose HCV viral load is negative based on the site-specific criteria will be allowed to be enrolled.) - Uncontrolled severe chronic infection or active infection 6. Prior or planned organ transplantation during the study period 7. Diagnosis of any malignant tumor other than the study indication within 5 years prior to screening (Patients who were treated and assessed as complete response [CR] without recurrence within 3 years or patients diagnosed with nonmelanoma skin cancer, in-situ disease, thyroid cancer, or borderline tumor will be allowed to be enrolled.) 8. Clinically significant, severe cardiac disease based on the judgment of the investigator (e.g., uncontrolled hypertension, congestive heart failure [NYHA Grade ≥2], ventricular arrhythmia, active ischemic heart disease, history of myocardial infarction within 1 year prior to screening), renal impairment, or respiratory disease

Gender: All

Minimum age: 19 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: National Cancer Center

Address:
City: Gyeonggi-do
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Bo-Hyun Kim, MD, PhD

Facility:
Name: Severance Hospital

Address:
City: Seoul
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Do-Young Kim, MD, PhD

Facility:
Name: SoonChunHyang University Hospital Seoul

Address:
City: Seoul
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Jae-Young Jang, MD, PhD

Facility:
Name: The Catholic University of Korea Seoul ST.MARY'S Hospital.

Address:
City: Seoul
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Pil-Soo Sung, MD, PhD

Start date: August 24, 2023

Completion date: December 2025

Lead sponsor:
Agency: Eutilex
Agency class: Industry

Source: Eutilex

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05783570